Solvonis Therapeutics plc

For @Solvonis , this patent: • Strengthens our #PTSD programme • Supports a broader protected chemistry estate • Adds flexibility as we advance SVN-114 $SVNS #Biotech #CNS #PTSD@

Recent sector activity — including Otsuka Pharmaceutical Co., Ltd.’s agreement to acquire Transcend Therapeutics for total potential consideration of US$1.225bn — underlines growing interest in next-generation #PTSD treatments.

🔬 @Solvonis granted U.S. composition-of-matter patent from its #PTSD discovery programme A meaningful IP milestone — these patents protect the underlying compounds themselves, widely regarded as the strongest form of patent protection in drug development. 🧵👇

SVN-114 wasn’t a one-off It emerged from systematic evaluation across @Solvonis' SVN-SDN-14 series — a novel, patent-protected compound class targeting SERT, DAT and NET Data-led selection. Platform-driven discovery #Biotech #CNS #DrugDiscovery 🔗solvonis.com/news/svn-114-s…

#PTSD affects millions globally, yet effective pharmacological treatments remain limited SVN-114 has been selected as the lead compound from @Solvonis' SVN-SDN-14 discovery programme, reflecting progress of its CNS discovery platform 🔗solvonis.com/news/svn-114-s… #Biotech #CNS

@Solvonis has selected SVN-114 as lead for its PTSD discovery program A novel compound targeting key monoaminergic pathways in the brain Program combines • Novel chemistry • Composition-of-matter IP • Multi-pathway CNS modul'n 🔗solvonis.com/news/svn-114-s… #DrugDiscovery #CNS

How does SVN-114 work? SVN-114 modulates 3 key brain systems: • SERT • DAT • NET Which regulate mood, emotional processing & social behaviour — all affected in PTSD SVN-114 is from our SVN-SDN-14 series, with comp-of-matter patents filed #biotech #CNS #PTSD

📺 Watch our CEO, Anthony Tennyson, discuss the selection of SVN-114 as the lead candidate in our PTSD discovery programme with @proactive_x #SVNS

Solvonis selects SVN-114 as lead candidate for its PTSD discovery program The compound demonstrated compelling preclinical pharmacology results, with balanced SERT/DAT/NET modulation. PTSD affects 20M+ people globally, with limited treatment options. solvonis.com/news/svn-114-s…

@Solvonis selects SVN-114 as lead #PTSD discovery program SVN-114 demonstrated compelling preclinical pharmacology results, with balanced SERT/DAT/NET modulation PTSD affects 20M+ people globally, with ltd treatment options solvonis.com/news/svn-114-s…

CEO @AnthonyTennyson on the expansion of SVN-015 into #depression: Preclinical antidepressant-like activity benchmarked against a gold-standard SSRI represents a notable signal supporting @Solvonis' strategic progression. $SVNS #Depression #CNS

Our CSO @ProfDavidNutt on SVN-015: Repeat-dose data benchmarked vs #fluoxetine support further development of a new #SDRI approach in #depression. 🔗solvonis.com/news/expansion… $SVNS #Biotech #CNSisComing

📺Watch: @Solvonis CSO, @ProfDavidNutt, discusses new SVN-015 data for use in depression and potential for patients who don't respond to SSRIs #SVNS

🔗solvonis.com/news/expansion…

SVN-015: ✅Demonstrated antidepressant-like activity benchmarked against fluoxetine (Prozac®) ✅Is expected to be developed as a once-daily oral therapy suitable for at-home use ✅Supports potential in patients with inadequate SSRI response

We are pleased to announce the expansion of SVN-015 into the treatment of depression following positive preclinical data! 💊SVN-015 is our novel patent pending SDRI ➡️Major Depressive Disorder affects more than c.20m adults in the US annually

📺 Watch our CEO, @AnthonyTennyson, discuss U.S. Patent allowance win for SVN-SDN-14 PTSD discovery programme with @proactive_x #SVNS

🔗 londonstockexchange.com/news-article/S…

U.S. Patent allowance received for our SVN-SDN-14 PTSD discovery programme ➡️ One compound being evaluated with lead compound expected to be selected in Q1 '26 ➡️ Strengthens intellectual property foundations ➡️ Demonstrates scientific & commercial significance